Literature DB >> 15224708

Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system.

Timothy A Simeone1, Russell M Sanchez, Jong M Rho.   

Abstract

Glutamate is the principal excitatory neurotransmitter in the mammalian central nervous system. After release from presynaptic terminals, glutamate binds to both ionotropic and metabotropic receptors to mediate fast, slow, and persistent effects on synaptic transmission and integrity. There are three types of ionotropic glutamate receptors. N-Methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA), and kainate receptors are principally activated by the agonist bearing its name and are permeable to cationic flux; hence, their activation results in membrane depolarization. All ionotropic glutamate receptors are believed to be composed of four distinct subunits, each of which is topologically arranged with three transmembrane-spanning and one pore-lining (hairpin loop) domain. In contrast, metabotropic glutamate receptors are G protein (guanine nucleotide-binding protein) -coupled receptors linked to second-messenger systems. Group I metabotropic glutamate receptors are linked to phospholipase C, which results in phosphoinositide hydrolysis and release of calcium from intracellular stores. Group II and group III metabotropic glutamate receptors are negatively linked to adenylate cyclase, which catalyzes the production of cyclic adenosine monophosphate. Each metabotropic glutamate receptor is composed of seven transmembrane-spanning domains, similar to other members of the superfamily of metabotropic receptors, which includes noradrenergic, muscarinic acetylcholinergic, dopaminergic, serotonergic (except type 3 receptors), and gamma-aminobutyric acid (GABA) type B receptors. This review summarizes the relevant molecular biology and ontogeny of glutamate receptors in the central nervous system and highlights some of the roles that they can play during brain development and in certain disease states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224708     DOI: 10.1177/088307380401900507

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  28 in total

1.  Metabotropic glutamate receptor blockade in nucleus accumbens shell shifts affective valence towards fear and disgust.

Authors:  Jocelyn M Richard; Kent C Berridge
Journal:  Eur J Neurosci       Date:  2010-12-29       Impact factor: 3.386

2.  The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Authors:  Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos
Journal:  J Invest Dermatol       Date:  2010-05-27       Impact factor: 8.551

3.  Neonatal treatment with a competitive NMDA antagonist results in response-specific disruption of conditioned fear in preweanling rats.

Authors:  Pamela S Hunt
Journal:  Psychopharmacology (Berl)       Date:  2006-01-17       Impact factor: 4.530

4.  Selective knockdown of NMDA receptors in primary afferent neurons decreases pain during phase 2 of the formalin test.

Authors:  J A McRoberts; H S Ennes; J C G Marvizón; M S Fanselow; E A Mayer; B Vissel
Journal:  Neuroscience       Date:  2010-10-23       Impact factor: 3.590

5.  Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans.

Authors:  Ye Wu; Amy C Arai; Gavin Rumbaugh; Anand K Srivastava; Gillian Turner; Takashi Hayashi; Erika Suzuki; Yuwu Jiang; Lilei Zhang; Jayson Rodriguez; Jackie Boyle; Patrick Tarpey; F Lucy Raymond; Joke Nevelsteen; Guy Froyen; Mike Stratton; Andy Futreal; Jozef Gecz; Roger Stevenson; Charles E Schwartz; David Valle; Richard L Huganir; Tao Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-07       Impact factor: 11.205

Review 6.  Domoic acid as a developmental neurotoxin.

Authors:  Lucio G Costa; Gennaro Giordano; Elaine M Faustman
Journal:  Neurotoxicology       Date:  2010-05-13       Impact factor: 4.294

7.  Differences between adolescents and adults in the acute effects of PCP and ketamine and in sensitization following intermittent administration.

Authors:  Angelica Rocha; Nigel Hart; Keith A Trujillo
Journal:  Pharmacol Biochem Behav       Date:  2017-04-22       Impact factor: 3.533

8.  A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5.

Authors:  Geoffrey Warnock; Michael Sommerauer; Linjing Mu; Gloria Pla Gonzalez; Susanne Geistlich; Valerie Treyer; Roger Schibli; Alfred Buck; Stefanie D Krämer; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

9.  From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Authors:  Randall J Platt; Kigen J Curtice; Vernon D Twede; Maren Watkins; Paweł Gruszczyński; Grzegorz Bulaj; Martin P Horvath; Baldomero M Olivera
Journal:  Toxicon       Date:  2014-02-07       Impact factor: 3.033

Review 10.  Pathophysiological and diagnostic implications of cortical dysfunction in ALS.

Authors:  Nimeshan Geevasinga; Parvathi Menon; P Hande Özdinler; Matthew C Kiernan; Steve Vucic
Journal:  Nat Rev Neurol       Date:  2016-09-23       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.